Press releases
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
On Tuesday, Organon & Co (0A9W:LSE) closed at 20.87, -13.22% below its 52-week high of 24.05, set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 20.87 |
Average volume | 1.71k |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.23 |
Market cap | 5.49bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 5.24% |
Div ex-date | May 09 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 20 minutes, as of Jun 04 2024 17:58 BST.
More ▼